In 2009, drug maker AstraZeneca’s Onglyza and Kombiglyze were approved by the FDA. The "incretin mimetic" is a well-known diabetes drug that works by increasing the body’s incretins, therefore increasing the release of insulin after meals. This is in hopes of lowering blood sugar spikes that usually occur after eating. The anti-diabetic medicine has raised several safety concerns in correlation with patients increased risk of health complications like heart failure, pancreatitis, pancreatic cancer, and thyroid cancer.
A SAVOR study involving 16,942 patients taking the drug, resulted in 1,222 of these patients who reported a major cardiovascular event. Since the study was proposed to show how drug-maker AstraZeneca’s drug, Onglyza, would not increase the risk of heart failure or other cardiovascular conditions – the ending results seemed to turn the table. The study concluded that those who were prescribed Onglyza, were 27% more likely to be hospitalized for heart failure or another heart-related event. Given that most of these patients are already exhibiting cardiovascular problems or liver damage, the use of Onglyza seems questionable to even use.
Patients who result in further health complications usually first endure some of the following symptoms:
Severe consequences include swelling of the kidneys(pancreatitis), growth and development of cancerous cells, heart failure, and lactic acidosis where lactic acid accumulates in the blood system. Lactic acidosis is caused by metformin, one of the ingredients in Kombiglyze. These effects are very fatal and can lead to death of a patient. To practice Onglyza & Kombiglyze safety, doctors are advised not to prescribe these drugs to patients who have had a heart attack in the past or is suffering from heart attack as this would worsen the situation. For Onglyza & Kombiglyze safety, they should be used in Type 2 diabetic adults and not in Type 1 diabetic cases. In addition, these patients can avoid these effects by doing Onglyza & Kombiglyze safety in that they can engage in healthy eating and regular exercising to avoid prevalence of the diabetic conditions.
In 2009, researchers started conducted studies to find out whether Onglyza can increase the risk of thyroid cancer. They found that there was a link, and this was placed on the warning label back in 2011. There have also been several other studies done to confirm that incretin-mimicking drugs can increase the risk of thyroid cancer. In fact, there was one study done that showed people who took incretin-mimicking drugs were 5 times more likely to develop thyroid cancer.
Pancreatitis is a condition that causes inflammation of the liver. Such condition can also increase the risk of pancreatic cancer. There was a study done in March 2013 that was published in a Diabetes journal. The study showed that people who took incretin-mimicking medications like Onglyza and Kombiglyze were 40 percent more likely to develop pancreatic problems.
The release of the SAVOR report resulted in the FDA voting 14 to 1, to increase the health risks within Onglyza’s package labeling as of then, April 2016. While the pharmaceutical company did supply the notion of increased health risks on its labeling, the company failed to label the increased cause in mortality among patients taking Onglyza. Furthermore, the monster pharmaceutical company did not label any restrictions on prescribing the drug.
Today, lawsuits are being filed against the pharmaceutical company for the following two reasons:
If you or a loved one has experienced any of the above symptoms, or health conditions due to antidiabetic medicines like Onglyza, contact our firm immediately. Above all, your health is the most important factor in this role. Don’t settle for less, we’re here to help.
-- Jack Ter-Saakyan, Esq.
Note: [Attorney Advertising] Nothing posted on this blog is intended, nor should be construed, as legal advice. Blog postings and hosted comments are available for general educational purposes only and should not be used to assess a specific legal situation. Nor does any comment on a blog post create an attorney-client relationship. The presence of hyperlinks to other third-party websites does not imply that the firm endorses those websites, their contents, or the activities or views of their owners.
Need professional legal assistance?
Look no further, we’d love to help.